Eighteen histone deacetylases (HDACs) are present in humans, categorized into two groups: zinc-dependent enzymes (HDAC1-11) and NAD ؉ -dependent enzymes (sirtuins 1-7). Among zinc-dependent HDACs, HDAC6 is unique. It has a cytoplasmic localization, two catalytic sites, a ubiquitin-binding site, and it selectively deacetylases ␣-tubulin and Hsp90. Here, we report the discovery that the redox regulatory proteins, peroxiredoxin (Prx) I and Prx II are specific targets of HDAC6. Prx are antioxidants enzymes whose main function is H2O2 reduction. Prx are elevated in many cancers and neurodegenerative diseases. The acetylated form of Prx accumulates in the absence of an active HDAC6. Acetylation of Prx increases its reducing activity, its resistance to superoxidation, and its resistance to transition to highmolecular-mass complexes. Thus, HDAC6 and Prx are targets for modulating intracellular redox status in therapeutic strategies for disorders as disparate as cancers and neurodegenerative diseases.
ighteen histone deacetylases (HDACs) have been identified in humans and classified based on homologies to yeast HDACs (1, 2) . Class I (HDACs 1, 2, 3, and 8), class II (HDACs 4, 5, 7, and 9), class IIB (HDACs 6 and 10), and class IV (HDAC11) are zinc-dependent deacetylases. Class III HDACs (sirtuins 1-7) are not zinc-dependent deacetylases and have an absolute requirement for NAD ϩ for their activity (3). HDAC6 is unique among the zinc-dependent HDACs (4) (5) (6) (7) (8) (9) (10) (11) (12) . It has a primary cytoplasmic localization, full duplication of its two catalytic sites, and a ubiquitin-binding domain at the C terminus. Inhibition of HDAC6 activity by the specific inhibitor, tubacin, or its down-regulation by siRNA, can increase accumulation of acetylated ␣-tubulin (6, 7) and can alter cellular mobility and can increase acetylated Hsp90 (8) (9) (10) , inducing client protein degradation. The ubiquitin-binding activity of HDAC6 mediates the recruitment of autophagic material to aggresomes, decreasing the cytotoxic effects of these aggregates (11, 12) . Thus, HDAC6 functions in various cellular processes that are dependent and independent of its catalytic activity and affects cell growth, migration, and cell death.
In this work, we made the discovery that HDAC6 has an important role in redox regulation and cellular stress response. We found that the redox regulatory proteins peroxiredoxin I (Prx I) and II (Prx II) are specific targets of HDAC6 deacetylase. Acetylated Prx I and Prx II accumulate in cells lacking HDAC6 deacetylase activity. We found that the prostate cancer cell (LAPC4) does not express HDAC6 protein. This finding was confirmed by siRNA knockdown of HDAC6 and by the specific inhibition of HDAC6 with tubacin (13) in a cell line, which expresses HDAC6 protein (LNCaP). Prx I and Prx II are highly homologous 2-cysteine members of the Prx protein family that function as antioxidants at low resting H 2 O 2 levels (14, 15). At higher levels of H 2 O 2, the cysteine residue can be oxidized to sulfonic acid, with transformation of these proteins to highmolecular-mass protein complexes. Prx I and Prx II are reported to be elevated in many cancers and in various neurodegenerative disorders (16) (17) (18) (19) (20) (21) (22) (23) . In cancer cells, Prx I and Prx II can confer resistance to chemotherapy and radiation therapy (15) (16) (17) (18) (19) (20) . Stress-related cellular dysfunction caused by reactive oxygen species (ROS) appears to be involved in the development of various neurodegenerative diseases (22, 23) .
We found that acetylation of Prx I and Prx II proteins increases their activity in reducing H 2 O 2 and increases their relative resistance to superoxidation and to transition to high-molecularmass complexes. At high levels of H 2 O 2 , Prx are transformed to large-molecular-mass complexes (14, 15) . HDAC6 and its specific targets Prx I and Prx II are shown to play an important role in modulating response to H 2 O 2 -induced cellular stress. This understanding of the specific deacetylase function of HDAC6 with Prx I and Prx II suggests that manipulating HDAC6 activity and, in turn, the redox activities of the 2-Cys Prx proteins, Prx I and Prx II, have an important potential in therapeutic strategies for cancers, neurodegenerative diseases, and other disorders that may involve cellular apoptosis.
Results
␣-Tubulin and 50-to 22-kDa Proteins are HDAC6 Targets. In studies (24) that determined the expression of the zinc-dependent HDACs in transformed and normal cells, we found that a human prostate cancer cell, LAPC4, did not express HDAC6 protein (Fig. 1A, lane 1) . All other zinc-dependent HDACs of class I, II, and IV were expressed in both the normal and transformed cells examined (24) .
To determine the basis of LAPC4 lack of expression of HDAC6 protein, Northern blot analyses were performed on lysates of these cells. No transcript of this protein was detected (data not shown). By using RT-PCR, HDAC6 transcript was detectable with two pairs of primers designed on the 3Ј origin [supporting information (SI) Fig. S1 A] . Using primers covering the entire transcript, we could not amplify the 5Ј end of the transcript corresponding to the CDS1 and CDS2 fragments compared with LNCaP cells (Fig. S1 A) . This finding is consistent with expression of a truncated HDAC6 transcript that could not be translated into a HDAC6 protein in LAPC4 cells.
Using an anti-acetylated ␣-tubulin antibody, we found that LAPC4 cells (Fig. 1 A, lane 1 ) accumulated acetylated ␣-tubulin and other acetylated proteins, ranging in size from Ϸ50 to 22 kDa. In three human prostate cancer cell lines that express HDAC6, Du145, LNCaP, and PC3, there was a low level of acetylated ␣-tubulin but no detectable acetylated proteins corresponding to 50-22 kDa (Fig.  1 A) . Noteworthy, SIRT2, an ␣-tubulin deacetylase (25) , is present in LAPC4 cells but apparently does not deacetylate the 50-to 22-kDa proteins (data not shown).
We next determined whether these acetylated proteins were deacetylase targets of HDACs by using suberoylanilide hydroxamic acid (SAHA, vorinostat), a paninhibitor of zinc-dependent HDACs (26) . LAPC4, Du145, LNCaP, and PC3 were cultured with or without SAHA. Lysates of these prostate cancer cells cultured with the HDAC inhibitor showed a similar pattern of acetylated proteins present in LAPC4 cells (Fig. 1B) . Thus, inhibition of HDACs, including HDAC6, is associated with the accumulation of acetylated proteins. Cells cultured without SAHA had low levels of acetylated ␣-tubulin and no detectable acetylated proteins corresponding to 50-22 kDa.
The following experiments were performed to determine whether the 50-to 22-kDa proteins are specific substrates of HDAC6. First, LNCaP cells were cultured with either SAHA, with tubacin, a specific HDAC6 inhibitor (13), or with MS-275, a
HDACi that inhibits class I HDACs but not HDAC6 (27) . LNCaP cells cultured with SAHA or tubacin, but not cells cultured with MS-275, accumulated acetylated ␣-tubulin and the 50-to 22-kDa proteins (Fig. 1C) . LNCaP cells cultured with SAHA or MS-275 but not cells cultured with tubacin-accumulated acetylated histones (data not shown). Second, LAPC4 cells transfected with HDAC6 gene, inducing expression of HDAC6 protein, had low levels of acetylated ␣-tubulin and no detectable 50-to 22-kDa acetylated proteins (Fig. 1D) . Third, LNCaP cells transfected with HDAC6 siRNA, resulting in decreased expression of HDAC6 protein, accumulated acetylated 50-to 22-kDa proteins (Fig. 1D ). These findings are consistent with the 50-to 22-kDa proteins being specific HDAC6 nonhistone protein substrates.
HDAC6 has two catalytic domains, and the second domain has been generally reported to be dominant for the deacetylation of ␣-tubulin (7, 13, 28) . A mutant HDAC6 with an inactive second tubulin catalytic domain (H611A) was transfected into LAPC4 cells. In these transfected cells, the expression of acetylated ␣-tubulin and the 50-to 22-kDa proteins was similar to that of nontransfected LAPC4 cells lacking HDAC6 proteins (data not shown). This finding suggests that the second catalytic domain of HDAC6 is required for the deacetylation of the 50-to 22-kDa proteins.
Identification of 22-kDa Proteins: Prx I and Prx II.
To identify the 50-to 22-kDa proteins, acetylated proteins were immunoprecipitated from cell lysates prepared from LAPC4 cells by using an anti-acetylated tubulin antibody. The immunoprecipitate was subjected to SDS/PAGE and stained with Coomassie blue. The band corresponding to the 22-kDa protein was recovered and analyzed by mass spectrometry (MS/MS) (29) . Two proteins were found, Prx I and Prx II, and we confirmed their presence in the immunoprecipitate from LAPC4 lysates by Western blotting using specific antibodies (anti-Prx I and anti-Prx II) ( Fig.  2A) . In cells cultured up to 48 h with SAHA or MS-275, the total expression of Prx I or Prx II was unchanged (data not shown).
To confirm that the 22-kDa proteins were acetylated Prx I and Prx II, their corresponding coding regions were cloned into a FLAG plasmid and overexpressed ectopically in LAPC4 cells. FLAG-immunoprecipitated proteins from lysates of transfected LAPC4 cells were analyzed by Western blotting with an anti- acetylated lysine antibody. The anti-acetylated lysine antibody specifically recognized Prx I and Prx II (Fig. 2B) .
Using recombinant Prx proteins, acetylated Prx I and Prx II were prepared by reacting them with histone acetyltransferase (HAT) and acetylcoenzyme A (acetyl-CoA). The acetylation of Prx I and Prx II was confirmed by Western blotting, using anti-acetylated lysine antibody (Fig. 2C) .
The intact positive charge of Lys 191 in the C terminus of yeast Prx is important for the reducing activity and resistance of the protein to superoxidation by H 2 O 2 (15, 30, 31) . We next tested whether the lysine residues in human Prx (Lys 197 in Prx I; Lys 196 in Prx II), corresponding to Lys 191 of yeast Prx, were acetylation sites. Mutants of recombinant Prx I were generated: K197Q (Gln is substituted for Lys and mimics acetylated lysine) and K197R (Arg is substituted for Lys and is a nonacetylated mimic) and reacted with HAT and acetyl-CoA (Fig. 2D) . A weak signal was detected in Prx mutant K197Q and in K197R, compared with wild-type Prx I. These findings indicate that the Prx I Lys 197 is an acetylation site. We also generated Prx II mutants (K196Q and K196R) cloned in a FLAG plasmid and transfected them into LAPC4 cells. The immunoprecipitates were analyzed by Western blotting using an anti-acetylated lysine antibody. The wildtype Prx II and the K196Q mutant presented strong positive signals, whereas the K196R mutant presented no detectable signal (Fig. 2E) . These results confirmed that Prx II Lys 196 is also a site of acetylation. The present results do not rule out that there may be other lysines in each protein that are acetylated.
Acetylation of Prx Increases Reducing Activity. We next evaluated the effect of acetylation of Prx I on its H 2 O 2 -reducing activity, using the peroxidase reaction with the thioredoxin (Trx) system as an electron donor, Trx reductase, and NADPH (32) (33) (34) . The activity of recombinant Prx I protein in reducing H 2 O 2 was assayed by measuring NADPH oxidation (absorbance at 340 nm) (30, 34) . The in vitro acetylated Prx I was more active than the nonacetylated Prx I in reducing H 2 O 2 over a range of 0.1-2.0 mM (Fig. 3A) .
Prx I and Prx II both regulate intracellular H 2 O 2 levels while at the same time are regulated by H 2 O 2 . Under normal redox conditions, Prx I and Prx II scavenge H 2 O 2 by building disulfide bridges that can be reduced via the thioredoxin system (30, (32) (33) (34) (35) (36) . At high levels of H 2 O 2 , Prx-reducing activity is lost through overoxidation of the active sulfhydryl site to sulfinic or sulfonic acid (33) (34) (35) . Upon overoxidation, Prx undergoes a transition to a high-molecular-mass complex (14) . Using an anti-Prx-SO 3 H antibody that specifically recognizes both sulfinic and sulfonic forms of overoxidized cysteine in Prx, we found that the acetylated Prx I was more resistant to inactivation by H 2 O 2 than the nonacetylated form of the protein (Fig. 3B) .
To test whether acetylation of Lys 197 was critical in determining of Prx H 2 O 2 -reducing activity, the effect of in vitro acetylation on the reducing activity of mutant Prx I proteins, K197Q and K197R, was assayed. Acetylation of the mutant proteins did not increase their reducing activity as it did in the wild-type protein (Fig. 3C) . The acetylated mimic mutant (K197Q) had a lower level of oxidized protein (assayed by reaction with anti-Prx-SO 3 H antibody) compared with the wild-type and K197R mutant proteins (Fig. 3D) . These findings indicate that acetylation of Lys 197 is involved in determining Prx-reducing activity and protection against overoxidation.
Overoxidation of Prx I or Prx II causes the loss of H 2 O 2 -reducing activity and the transition to high-molecular-mass complex protein (14, 15) . LNCaP cells exposed to concentrations of 50 and 100 M H 2 O 2 for 20 min accumulate high-molecular-mass complexes of Ϸ480 kDa (Fig. 4A) . By comparison, in LAPC4 cells, which have acetylated Prx, the high-molecular-mass complexes accumulate only when they were exposed to 100 M H 2 O 2 , but not 50 M H 2 O 2 ( Fig. 4A) . Similar results were found for Prx II (data not shown). The level of overoxidized Prx (anti-Prx-SO 3 H) was lower in LAPC4 cells compared with LNCaP cells (Fig. 4A) , which is consistent with acetylated Prx in LAPC4 cells being more active in H 2 O 2 -reducing activity and being more resistant to overoxidation and transition to the high-molecular-mass complexes.
To confirm that the lower level of oxidized Prx in LAPC4 H 2 O 2 -treated cells was associated with Prx acetylation, Prx IIflagged proteins (wild type and mutants) were overexpressed in LNCaP cells and then treated with H 2 O 2 . The Prx II K196Q acetylated mimic formed high-molecular-mass complexes only at 100 M H 2 O 2 whereas in the wild type and K196R mutant the complexes formed at 50 and 100 M H 2 O 2 (Fig. 4B) . Acetylation of Prx is a major determinant in its protection from overoxidation.
Sensitivity to H2O2-Induced Cell Death of LAPC4, LNCaP, and Normal
Human Foreskin (HFS) Cells. ROS are generated in cells in response to several types of environmental stress that lead to apoptosis and cell death (37) . Prx I and Prx II play a role in modulating cellular response to ROS (30, 31) . LAPC4 cells, in which there is an accumulation of acetylated Prx I, H 2 O 2 concentrations (0.5 mM) that induce 100% of LNCaP and HFS cells to undergo apoptosis and cell death (Fig. 5A ) induces Ͻ10% LAPC4 cell death. LNCaP (Fig. 1 A) and HFS cells (data not shown) lack detectable acetylated Prx (22-kDa) proteins. When LAPC4 cells were transiently transfected with HDAC6 gene and expressed HDAC6 protein (Fig. 1D) , H 2 O 2 (0.5 mM) induced Ͼ40% of the cells to undergo cell death (data not shown). When HDAC6 was inhibited in LNCaP cells by tubacin or transient transfection with HDAC6 siRNA, acetylated Prx accumulated (Fig. 1 C and D) . LNCaP cells were significantly more resistant to H 2 O 2 -induced cell death when HDAC6 activity was inhibited by tubacin (at 24 h, P ϭ 0.004) (Fig. 5C Upper) or by HDAC6 siRNA compared with control cells (at 24 h, P ϭ 0.014) (Fig. 5C Lower) . The loss of viability was greater in cultures of cells transfected with siRNA than cells exposed to tubacin, which may reflect the manipulation required for siRNA transfection. In both studies, inhibiting HDAC6 was associated with significant increased resistance to H 2 O 2 .
Poly(ADP-ribose) polymerase (PARP) degradation is a marker of cellular apoptosis (37) . PARP was assayed in lysates of LNCaP cells cultured with and without tubacin for 4 h and then exposed to 0.1 mM H 2 O 2 for 48 h. Cells cultured with tubacin plus H 2 O 2 had nondegraded PARP (Fig. 5D) , similar to the pattern observed in cells not exposed to H 2 O 2 . LNCaP cells exposed to H 2 O 2 without prior culture with tubacin had degraded PARP (Fig. 5D) . Thus, inhibition of HDAC6 activity is associated with resistance to H 2 O 2 -induced apoptotic cell death.
Discussion
This work describes the discovery of a function for HDAC6, namely the specific deacetylation of redox regulatory proteins Prx I and Prx II. Previous studies established that HDAC6 is the deacetylase for ␣-tubulin, cortactin, an actin binding protein and the chaperone protein Hsp90 (6-10). In addition to its deacetylase activity, HDAC6 has a ubiquitin binding site at its C terminus that can play a role in facilitating autophagic degradation of potentially noxious proteins (11, 12) .
The present discovery that the redox regulatory proteins Prx I and Prx II, whose main function is cellular protection from free radical accumulation, are specific substrates of HDAC6 adds an important understanding of the functions of this deacetylase that has implications for diseases as disparate as cancers and neurodegenerative disorders.
The human prostate cancer cell LAPC4 lacks HDAC6 protein and accumulates the previously unrecognized substrates of HDCA6, acetylated Prx I and Prx II. Inhibition of HDAC6 with tubacin or its down-regulation with siRNA in both transformed cells (LNCaP, PC3, Du145) as well as normal cells (HFS) was associated with an accumulation of acetylated and Prx I and Prx II. Prx I are elevated in many cancers including esophageal, pancreatic, melanoma, thyroid, and lung cancers (16) (17) (18) (19) (20) . Elevated levels of Prx I and Prx II are associated with resistance to cancer therapy and promote aggressive survival phenotypes of cancer cells.
Prx have also been reported to be overexpressed and/or aberrantly expressed in several neurodegenerating disorders, including Alzheimer's, Pick's disease, and others associated with progressive aggregate formation (22, 23) . The present work found that the acetylated form of Prx is more active in reducing H 2 O 2 than the nonacetylated form. Thus, inhibition of HDAC6 deacetylase activity with a consequent accumulation of acetylated Prx could lead to a beneficial increase in antioxidant activity in neurodegenerative disorders. HDAC inhibitors such as SAHA, trichostatin A, and sodium butyrate have been shown to ameliorate disease progression in rodent models of Huntington's disease (38) , spinal and bulbar muscular atrophy (39) , amyotrophic lateral sclerosis (40) , and Parkinson's disease (41) . Although the mechanisms of the beneficial effects of the HDAC inhibitors in these neurodegenerative diseases are not known, inhibition of HDAC6 with consequent increase in Prx reducing activity may, in part, explain these effects.
However, in cancer cells, the increased reducing activity of Prx associated with inhibition of HDAC6 could contribute to resistance to therapy. This hypothesis would suggest that as part of an anticancer therapeutic regimen, inactivating Prx activity might be beneficial (42) (43) (44) (45) .
In summary, the discovery that HDAC6 is a specific deacetylase for the redox regulatory proteins Prx I and Prx II whose activity is regulated, in part, by acetylation, suggests that the activity of this deacetylase and of the redox proteins can be useful targets for therapeutic strategies in these disparate disorders. The redox proteins, Prx, have a role in both the resistance of certain cancers to therapy and quite a different role in possibly slowing the progression of neurodegenerative diseases. Developing inhibitors of Prx acetylation may be a useful therapeutic strategy for cancers. However, an agent such as a specific HDAC6 inhibitor that enhances the accumulation of acetylated Prx and protects these proteins from overoxidation may be useful in treating neurodegenerative disorders that involve apoptotic cell death.
Methods
Cell Lines, Reagents, and Antibodies. LNCaP, Du145, PC3, and HFS were obtained from American Type Culture Collection. LAPC4 cells were kindly provided by Charles Sawyers (Memorial Sloan-Kettering Cancer Center). Antibodies used were: anti-acetylated tubulin (Sigma), anti-HDAC6 (Santa Cruz Biotechnology), anti-tubulin, (Calbiochem), anti-acetylated lysine (Cell Signaling), anti-Prx I and Prx II (Upstate), anti-Prx-SO 3H (Abcam), anti-PARP (BD Biosciences). MS-275 was obtained from Calbiochem. Tubacin and SAHA were kindly provided by Stuart Schreiber (Harvard University, Cambridge, MA) and Ronald Breslow (Columbia University, New York), respectively.
Western Blotting and Immunoprecipitation. Western blotting was performed as published in ref. 24 . Immunoprecipitation was performed either by using the anti-acetylated tubulin antibody, which was covalently bound to CNBr-activated Sepharose 4B beads according to the manufacturer's instructions (Amersham), or by using anti-FLAG beads (Sigma). Cell lysate and beads were incubated overnight at 4°C. Bound proteins were eluted by competition with 100 g/ml specific peptide. For protein identification, different elution fractions were fractionated in SDS/polyacrylamide gels. Gels were stained with Coomassie blue R-250, and visible bands were cut and submitted to mass spectrometry analyses (29) .
Transfections. HDAC6 vectors were kindly provided by Stuart Schreiber. Prx I and Prx II coding region sequences were amplified by using cDNA from LAPC4 cells. The primers used for RT-PCR were: Prx I forward (5Ј-ggaagcttatgtcttcaggaaatg-3Ј), Prx I reverse (5Ј-ccgaattctcacttctgcttggag-3Ј), Prx II forward (5Ј-ggaagcttatggcctccggtaacg-3Ј) and Prx II reverse (5Ј-ccgaattcctaattgtgtttggag-3Ј). They were cloned into the pFLAG-CMV-4 vector (Sigma). Prx mutants were generated by using the QuikChange II site-directed mutagenesis kit (Stratagene). HDAC6 siRNA and nonsilencing oligonucleotides were obtained from Qiagen. Cells were transfected by using the Nucleofactor kit (Amaxa), following the manufacturer's instructions.
In Vitro Acetylation. In vitro acetylation of Prx was performed by using 10 g of Prx recombinant protein incubated at 30°C for 20 min with 2 g of p300 HAT domain (Upstate) and 1.2 mM acetyl-CoA (Sigma) in a buffer containing 50 mM Tris⅐HCl (pH 8.0), 10% glycerol, 0.1 mM EDTA, and 3 mM DTT, in a 45-l final volume.
Peroxiredoxin Activity. Peroxidase activity was measured by monitoring the oxidation of NADPH by the decrease of absorbance at 340 nm (21) . The reaction was carried out by using 50 mM Hepes-NaOH (pH 7.4), 3 g of Trx reductase (Sigma), 4 g of Trx (Sigma), 0.5 mM NADPH (Sigma), 5 g of Prx I (BPS Bioscience), and different concentrations of H 2O2 in a 150-l final volume.
H2O2 Treatment and Prx
High-Molecular-Mass Complex Detection. Cells were seeded in 24-well plates at 5 ϫ 10 4 cells per well and treated the day after, as follows. Chemical inhibition of HDAC6 activity was done by pretreatment with 8 M tubacin for 4 h before H2O2 treatment. In the HDAC6 down-regulation experiment, cells were transiently transfected with HDAC6 siRNA or nonsiRNA oligonucleotides and allowed to recover for 2 days and then treated with H 2O2. Cell viability was evaluated by Trypan blue assay (45) . Prx oligomers were identified after cells were treated with H 2O2 for the appropriate times and concentrations. Cell lysates were fractionated in nondenaturing gels (Invitrogen) and analyzed by Western blotting as described in ref. 24 .
